INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is a bacterial pathogen that causes a large burden of disease globally. Currently-available protein-polysaccharide conjugate vaccines target 13 of the more than 95 identified serotypes. The vaccines reduce the frequency of colonization due to vaccine-targeted serotypes and subsequently reduce disease [1] . There is a need to perform surveillance to monitor declines in vaccine-targeted serotypes as well as to detect increases in disease caused by serotypes not targeted by the vaccine (serotype replacement). The gold-standard is to monitor the incidence of invasive pneumococcal disease, a rare but severe outcome where the bacteria are isolated from a normally sterile site, such as the blood or cerebrospinal fluid. However, conducting such disease surveillance in low-resource settings is often not feasible. Therefore, it is often necessary to use other indirect measures of serotype epidemiology and vaccine effects. One such indirect measure is to track the prevalence of serotypes among healthy children who carry pneumococcus in the nasopharynx [2] . Because pneumococci are commonly detected among healthy children, point prevalence studies can be used to track changes in exposure to the different serotypes [3, 4] .
Carriage-based surveillance typically involves collecting a nasopharyngeal swab from a child, culturing it in the laboratory, isolating a pneumococcal colony, and then performing a traditional serotyping method such as the Quellung reaction, an antibody-based assay to determine the serotype of the isolate [5] . Quellung is relatively time consuming to perform, particularly when trying to test multiple colonies per sample. More recently, DNA based approaches have been used to determine the serotype of the isolated strain such as conventional and real-time PCR assays have been developed to identify common serotype and/or serogroups [6, 7, 8] .
Whole-genome sequencing can effectively determine the serotype of single isolates, and several pipelines (PneumoCaT and SeroBA) have been developed [9, 10] . A microarray-based platform can detect and quantify the relative abundance of all serotypes in a sample [11] . This is a highly-sensitive and accurate method and outperforms many other serotyping approaches [12] .
The downside of this technology is that it requires specialized equipment that cannot be readily implemented by different labs. An ideal solution could be a sequencing-based approach that could be used to identify multiple serotypes in mixed samples and to quantify their abundance.
Low-cost Illumina sequencing library preparation protocols make such an approach feasible and cost effective [13] , and whole-genome sequencing is increasingly being adopted for diagnostic and public health applications [14] . The major challenge is a bioinformatic one: how to accurately identify and quantify serotypes in mixed samples.
The bioinformatic challenge revolves around the similarity of portions of the sequences in the capsular biosynthesis cassette in multiple serotypes. Only 25 of the 94 serotype capsular sequences are genetically distinct, while the rest form "serogroups" of genetically similar but phenotypically different serotypes [9] . The similarity is such that over 70% of error-free reads from those groups cannot uniquely map to a specific serotype, and several phenotypically distinct serotypes differ by only a single base pair over their 10-25 kb capsular sequence. Thus, traditional read mapping approaches fail, as they assume that nearly all informative reads will map uniquely. PneumoCaT and SeroBA can accurately identify serotypes from Illumina whole-genome sequencing reads. However, they expect "pure" samples (95% or more of the sample consists of a single serotype), do not provide quantitation, and will simply report "mixed" if the sample is found to contain multiple serotypes. In this study we develop and test an analysis approach and a software tool, SeroCall, for quantifying serotype abundance based on raw Illumina sequencing reads. We first use existing datasets and spiked samples in the lab to develop the pipeline. We then test the performance of this approach using a reference set of blinded gold-standard laboratory-prepared samples that have known quantities of different serotypes.
METHODS

Experiments with known serotype composition
The first set of dilution and competition experiments used invasive pneumococcal disease isolates that were obtained from the CDC's Active Bacterial Core surveillance system isolate bank (1, 3, 4, 6B, 7F, 9V, 14, 18C, 19F, 23F). The strains were grown overnight on TSAII plates with 5% sheep's blood at 37 o C with 5% CO 2 .
Mixture with known concentrations of DNA
Overnight growth was harvested in PBS, and genomic DNA was extracted using a DNEasy blood and tissue kit (Qiagen) with the Gram positive pretreatment protocol. DNA was quantified using a NanoDrop reader (ThermoFisher). Serotypes were then mixed together at the following ratios 
Longitudinal growth experiment
Overnight growth on TSAII plates was resuspended in PBS, and the optical density (OD) at 600nm was adjusted to 0.05. These stocks were then diluted 1:20 into a diluted broth of 7.5mL PBS, 2.5mL BHI, 8.25uL sheep blood, and 125uL horse serum. The strains were grown individually for several hours until the lowest concentration strain reached OD ~0.15. All strains were adjusted down to match this value. The strains were then mixed at equal concentration and diluted 1:20 into fresh broth in deep well plates (800 uL broth + 40uL bacteria) with a separate replicate well for each time point. The plate was then incubated at 37 o C with 5% CO 2 . 40uL from each well of the 6h time-point was used to seed a new row of 800uL broth to allow another 2 hours of growth. This passaging step is important because in the limited nutrient broth, pneumococcal population tends to crash after 6 hours. At the indicated time points, the full volume of the well was transferred to the -80 °C freezer. At the end of the experiment, DNA from all wells was extracted at the same time using a Qiagen DNEasy blood and tissue kit with Gram positive pretreatment protocol (Qiagen). The experiment was performed in duplicate.
Single serotype calls and benchmarking against other serotyping software
The development and validation whole-genome sequencing datasets that were used in [9] to develop and test the PneumoCaT and SeroBA software were used similarly here. 871 development samples, covering all 94 serotypes, were used in the development of the SeroCall software, and then the 2065 validation samples covering 72 serotypes were evaluated using the final version of the software. Also, the current versions of PneumoCaT (v1.2) and SeroBA (v1.0.1) were run locally on all samples, and the "gold standard" calls used for benchmarking were the majority vote of the original laboratory serotyping, the PneumoCaT call and the SeroBA call. This accounts for updates to the software that correct for serotypes reported at the time of the PneumoCaT publications (most notably, a change in the 12B vs. 12F typing that was discovered after the publication of [9] ).
Evaluation with blinded samples
The PneuCarriage Project [12] was a multi-center study to evaluate pneumococcal serotyping methods. A set of standard laboratory-prepared sample mixtures has been evaluated using a large number of serotyping methods. Eighty of these samples, containing mixtures of 0-4 serotypes, were evaluated using our analysis pipeline. The laboratory personnel processing the samples and the bioinformatic analysts were blinded to the serotype composition of the samples.
The samples were provided as frozen aliquots. Samples were thawed, 10-fold dilutions were spread on a TSAII plate with 5% sheep's blood, and incubated overnight at 37 o C with 5% CO 2 .
The most concentrated non-confluent dilution was harvested into PBS, and DNA was extracted as described above. During the culturing and preparation, 9 of the serotype-positive samples failed to culture, and a further 6 samples failed amplification due to an existing primer failure.
The remaining 65 samples were sequenced to an average of 1.90 million reads per sample; a second round of sequencing increased the average reads per sample to 4.67 million reads per sample. Serotype calls and quantifications were returned for all samples and evaluated by PneuCarriage Project personnel.
Library preparation
Illumina libraries were prepared using the protocol described by Baym, et. al . [13] . The exception was that the final cleanup was performed using Qiagen PCR purification columns rather than the bead-based assay described in the original paper. The sequencing indices that were used are listed in the supplemental material. Each plate of up to 96 samples were multiplexed and run on an Illumina HiSeq with a read length of 2x150bp.
Bioinformatic approach
The overall steps of the SeroCall software follow that of PneumoCaT and SeroBA, but apply different algorithms in order to quantify all serotypes found in a sample. All of the tools (1) align the read data to the set of serotype capsular sequences, (2) identify serogroups and distinct serotypes that are present in the sample, and (3) distinguish serotypes within the serogroups, using serotype-specific variants or regions of the capsular sequences.
Step 1 -Read Alignments
Sequence read data are first aligned using BWA MEM [15] to a "reference" that combines the serotype capsular sequences from 94 serotypes with the non-capsular sequences from three S. pneumoniae genomes: R6, SPNA45 and ATCC700669 (where the capsular sequence from each has been masked). The supplementary material details the capsular reference sequences used, most of which are the same as the PneumoCaT reference sequences, but several have been modified to work with this algorithm. The genome sequences mainly serve as a "decoy", so that genomic reads will align to the genome sequences instead of to the capsular sequences, and so will not affect the read depths for the serotypes.
The read alignments produced by BWA MEM are used to compute "bin counts," counting the total and uniquely-mapped reads across the serotype capsular sequences. Each sequence is partitioned into 500 bp bins, denoted S i,b for serotype i and bin b. The choice of 500 bp ensures that local depth variations resulting from sequencing are smoothed in the bin counts. Read alignments are processed in read-pairs, and are first filtered for (1) any genomic alignments, (2) any unmapped alignments (if either read in a read pair is unaligned, then both reads in the pair are filtered), (3) any chimeric reads aligning to two different serotypes, or (4) any read pairs with a combined 10 or more differing or soft clipped bases, as this is a sign of a genomic read pair mistakenly aligned to a serotype sequence.
The remaining read-pair alignments add to bin counts, incrementing the counts of any bin which overlaps with either of the read alignments. The "total bin counts" count both uniquely mapping reads (reads whose MQ >= 0) and repetitively mapping reads (could map equally well to multiple locations in the serotype sequences, where the BWA MEM software randomly chooses a location from those best locations). The "unique bin counts" count only uniquely mapping reads. For an input sequence dataset, this results in T i,b and U i,b matrices containing the bin counts for that data.
Step 2 -Serotype/Serogroup Quantification The second step takes the bin counts from the input data, treating them as the "observed" counts OT i,b and OU i,b , and compares them against the sets of "expected" counts ET y,i,b and EU y,i,b for all serotypes y (because of the similarity between serotype sequences, reads from a serotype y will align to serotype i, and so will contribute to the bin counts for serotype i). These expected counts were determined by generating simulated reads for each serotype and computing the bin counts for those reads. Specifically, a simulated 2x100bp read-pair (with an insert size of 200 bp) was generated at every position of a serotype's capsular sequence, so that each location of the capsular sequence is covered by 200 reads across the whole sequence, except at the ends.
Generating bin counts in this way results in expected bin counts for an equal 200x sampling of each serotype.
The comparison uses expectation-maximization to compute the optimal "factor levels" F y for each serotype y, which optimize the equations:
In other words, it computes the factor levels that result in a mixture of the expected serotype bin counts which most closely resembles the observed bin counts. Initially, all F y are set to 1.0, then 100 rounds of a gradient descent algorithm is performed, computing the expected mixture bin counts, comparing them to the observed counts and adjusting the factor levels up or down. the observed counts across all of the bins. Per-serotype factor ratios, ratioT i and ratioU i , are then computed using a weighted median of the bin ratios for the serotype, where the weights for each bin are ET i,i,b / maxET and EU i,i,b / maxEU (i.e., the fraction of total/unique reads coming from serotype i and bin b that were actually counted in the bin). This gives higher weight to the more unique, or less repetitive, regions of each serotypes' capsular sequence. And, the median is used instead of the mean in order to prevent genome contamination and local genetic differences (serotype samples whose actual capsular sequence mainly matches the reference, but which contains a local region unique to another serotype) from skewing the quantitation.
Final serotype ratios are computed by combining the ratioT and ratioU values based on the bin with the highest unique weight, i.e., mW i = max b ( EU i,i,b / maxEU ). And so, ratio i = mW i * ratioU i + (1.0 -mW i ) * ratioTi. Then, new factor levels are computed as F i = F i + ( F i -F i * ratio i ) / 2, adjusting the factor level by half of the computed observed over expected ratio, in each round of the gradient descent. Also, if at any point, F i falls below 0.002, it is set to 0.0.
Step 3 -Serogroup Refinement
The third and final step readjusts the factor levels for the serotypes within serogroups that cannot be distinguished based on bin-sized read depth differences. The method of Steps 1 and 2 are able to distinguish 56 of the serotypes without further refinement, and the groups of serotypes that require further refinement by this method are: 6A/6B/6C/6D/6E; 7A/7F; 7B/40; 9A/9V; The reason for the translation is that this step of the algorithm takes advantage of the sensitivity of BWA MEM in aligning reads to near-identical locations in the reference. If there is a single location whose alignment contains more identities than all other locations, that "best match" location will be chosen. Even a single nucleotide difference is sufficient for BWA MEM to consistently align reads to the proper serotype's sequence, and so the read depths at those difference locations provide an accurate measure of the differences between serotypes. So, instead of performing a separate variant calling, mapping or de novo assembly to resolve serotypes, the computation of Step 1 computes "bin" counts at these specific difference locations, and then this step compares the observed counts at those locations against the expected counts.
Since these locations are where the serotypes are genetically different, and alignment "bleed" is not an issue, this step just computes depth ratios for each serotype and difference location in a group, where OU / EU is used if EU is greater than 0, and OT / ET is used otherwise. The ratio for a serotype is the minimum of the computed depth ratios across the difference locations (if the serotype is present in the sample, each of these locations should have a non-zero read depth).
Then, those ratios are summed, and serotype percentages are computed by dividing the serotype ratio by the sum of the ratios.
If the sum of the ratios is 0, this means that there is no read evidence distinguishing the serotypes in the group, and an ambiguous call like "09A/09V" is made, with a factor level equal to the sum of the factor levels computed in step 2, for the serotypes in the group. If the sum is greater than 0, then the factor levels from step 2 (again, for the serotypes in the group) are reapportioned using the serotype percentages computed in this step. So, for example, if 09A and 09V had step 2 factor levels of 0.13 and 0.11, but the step 3 serotype percentages were 80% 09A and 20% 09V, then the factor levels would be changed to 0.192 for 09A and 0.048 for 09V (to maintain the 09A/09V levels compared to all other serotypes, but reset the serotype-specific levels to the identified percentages).
Once the final factor levels are computed, they are converted to percentages by dividing each by the sum of all factor levels. Then, any serotype with a percentage less than 0.2% is filtered out, and the percentages are recomputed using only the remaining serotypes. Those serotypes and percentages form the output calls produced by the software.
Data and software availability
The PneumoCaT serotype datasets can be accessed through the European Nucleotide Archive 
RESULTS
Single serotype calls using sequences in the PneumoCaT database
For the 871 development samples, the calls made by SeroCall had a concordance rate of 96.1% at the serotype level and 98.6% at the serogroup level, with 816 exactly matching calls, 21 samples with only minor differences (i.e., a matching serotype call with abundance above 95%, which is the PneumoCaT threshold for reporting a "pure" serotype, plus additional calls with total abundance below 5%), 22 samples with multiple or different serotypes called from the matching serogroup, and 12 "discrepant" samples.
For the 2065 validation samples, the concordance rate was 97.0% at the serotype level and 98.9% at the serogroup level, with 1924 exactly matching calls, 79 samples with minor differences, 40 samples with multiple/different serotypes from the matching serogroup called, and 22 "discrepant" samples. The details of all non-matching samples for both datasets can be found in the supplementary material.
The average, minimum and maximum execution times for SeroCall, SeroBA and PneumoCaT are given in Table 1 , for the analysis of the development samples (the validation sample running times were similar). All software was run on 20 core, 121 GB memory, "2x E5-2660 v3" compute servers, where the software was run with exclusive access to the server. The SeroCall and PneumoCaT command lines were passed "-t 20" options, allowing them to use 20 parallel threads. For this dataset on these servers, SeroCall ran three times faster than SeroBA and twice as fast as PneumoCaT. The computation in SeroCall is dominated by the BWA MEM alignment, which scales linearly in the number of cores. So, on compute servers with 8 or more cores, SeroCall is expected to run as fast or faster than SeroBA.
Running time (MM:SS)
SeroCall SeroBA PneumoCaT 
Mixed samples with known concentrations
Mixtures of DNA were prepared, containing known fractions of 2, 3 and 5 different serotypes.
SeroCall was able to accurately recover the true fraction of each serotype, including serotypes that were present at a low fraction ( Figure 1 ).
Blind testing of mixed serotype samples from the PneuCarriage project
Fifteen of the 80 PneuCarriage samples either failed to grow (n=9) or had other technical issues during library preparation (n=6). In keeping with the blind testing, results from all samples were returned to the PneuCarriage project and evaluated. Here we outline the results of the 65 samples that were successfully cultured, prepared and sequenced. The supplementary material details the full evaluation of all 80 samples. Table 2a shows the sensitivity of the assay, both with a first round of sequencing, along with a second round of sequencing that increased the average reads per sample. The sensitivity to detect the major serotype was 98% and 100% for the first and second rounds of sequencing, respectively. Samples containing serotype 12F were misidentified as 12B, as the version of SeroCall used in this testing was based on the original CTV database from the PneumoCaT paper [9] . The sensitivity to detect minor serotypes was 59% using only the 1.9 million reads per sample (first round), and improved to 81% with 4.67 million reads per sample (second round).
However, that came at the cost of an increase in false positive identifications. Excluding 12F/12B misidentifications, there was one false positive in the first round (resulting in a positive predictive value (PPV) of 96%) but six false positives in the second round (PPV of 95%).
Finally, the quantitation of the serotype calls was evaluated against the known spiked levels for 32 multi-serotype samples called correctly (using the second round data). The correlation between the two was strong (Spearman's p = 0.762, p < 0.0001), and the mean absolute difference between the known level and the SeroCall quantitation was 4.0% ( Figure 2) . Note, because of a primer failure, only single results were generated for the 10 serotype sample at 6 hours and 8 hours.
DISCUSSION
We developed and validated a whole-genome sequencing method and analysis software SeroCall [18] . As such, future work will evaluate SeroCall using nasopharyngeal samples, for example the PneuCarriage field samples (aliquots of STGG from NP swabs) . Finally, improvements and increased testing of the laboratory methodologies, including the use of non-duplicate Illumina index primers and potentially side-by-side comparison of microarray and sequencing of the same DNA, to explore differences in DNA extraction efficiency, may increase the robustness of the method.
One experimental parameter that affects the results is the read depth. Using the blinded samples, we found that with a low read depth, the sensitivity to detect minor serotypes was greatly reduced. We recommend obtained a read depth of 2-3 million reads per sample to obtain sensitivity similar to what is reported here, and possibly higher depth if looking for very low abundance serotypes. The 'cost' of increased read depth was an increase in the number of false-positive identifications of rare serotypes. One possible explanation for the false positives is
Illumina "barcode hopping" [19] , as the library preparation used standard multiplex primer sequences which have been found to be susceptible to that. Using unique barcode pairs for each sample could help to avoid this issue and allow for detection of low abundance serotypes without an increase in false positivity.
The library preparation protocol that we use, which was developed by Baym et al. [13] , can produce high-quality, low-cost sequences when multiplexing samples. Provided that an investigator has access to an Illumina sequencer, this makes performing sequence-based serotyping cost effective when compared with traditional serotyping methods.
During sample preparation we lost several samples. 9 of the blinded samples failed to culture.
This could have been an issue with sample transport or with the culture conditions in the lab. We also lost several samples due to a primer failure during the library preparation. Confirming the concentration of each sample prior to pooling would catch this issue prior to pooling to allow for re-generation of the libraries for the affected samples.
In conclusion, we describe the development of an analytical tool that can be used to quantify the abundance of multiple serotypes in mixed cultures using a sequencing-based approach. We do this by addressing a bioinformatic challenge in assigning Illumina reads from a mixed sample to the correct serotype. This method could be applied to epidemiologic studies of pneumococcal carriage that seek to evaluate the carriage frequency of dominant and sub-dominant serotypes and can be used to monitor changes associated with the introduction of conjugate vaccines.
